Статья

POS-320 EFFECTIVENESS AND SAFETY OF RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH OBESITY, TYPE TWO DIABETES AND CKD

Sherzod AbdullaevRepublican Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Immunogenetics, Tashkent, UzbekistanRanokhon IgamberdievaTashkent pediatric medical institute, Internal medicine, Tashkent, Uzbekistan

Kidney International Reportsjournal2022en

ABI

Аннотация

We aimed to evaluate the clinical characteristics and outcomes of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concurrent obesity, type two diabetes (T2D) and chronic kidney disease (CKD)

Перевод пока недоступен

Темы

Atrial Fibrillation Management and Outcomes

Идентификаторы

DOI: 10.1016/j.ekir.2022.01.341

Цитирования и источники

Цитирований: 0Использованных источников: 0

Показатели — AkademScholar · Скоро